World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
47961
World Ranking
12906
National Ranking
1211

Overview

Kei Muro is affiliated with the National Cancer Research Institute, UK in the United Kingdom. Their research primarily spans the field of Medicine with a strong focus on Oncology and related subfields.

Muro's main areas of research include Oncology, Pulmonary and Respiratory Medicine, Surgery, Gastroenterology, and Cancer Research. Within these, key topics addressed are Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Esophageal Cancer Research and Treatment, Gastrointestinal Tumor Research and Treatment, Lung Cancer Treatments and Mutations, and Cancer Treatment and Pharmacology.

Their frequent co-authors include Shigenori Kadowaki, Toshiki Masuishi, Yukiya Narita, Kentaro Yamazaki, and Takatsugu Ogata, indicating ongoing collaborative research efforts in their field.

Kei Muro has contributed to several recent papers demonstrating a focus on immunotherapy and clinical trials in gastrointestinal and colorectal cancers:

  • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer, 2020, Journal of Clinical Oncology
  • Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials, 2021, JAMA Oncology
  • Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer, 2023, JAMA
  • Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study), 2020, Journal of Clinical Oncology
  • Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial, 2021, Gastric Cancer

Their publication record includes frequent contributions to the following journals:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Gastric Cancer
  • Esophagus
  • International Journal of Clinical Oncology

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    Kei Muro;Hyun Cheol Chung;Veena Shankaran;Ravit Geva

  • Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Laura Q.M. Chow;Robert Haddad;Shilpa Gupta;Amit Mahipal

  • Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.

    Y Matsumura;T Hamaguchi;T Ura;K Muro

  • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    Takashi Kojima;Manish A Shah;Kei Muro;Eric Francois

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • EJ-3Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

    Kei Muro

  • Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study

    Atsushi Ohtsu;Jaffer A. Ajani;Yu Xian Bai;Yung Jue Bang

  • Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

    T. Yoshino;D. Arnold;H. Taniguchi;G. Pentheroudakis

  • Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

    Ryan B. Corcoran;Thierry Andre;Chloe E. Atreya;Jan H.M. Schellens

  • Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus

    Atsushi Ohtsu;Narikazu Boku;Kei Muro;Keisho Chin

  • BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

    T Yokota;T Ura;N Shibata;D Takahari

  • Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

    Toshihiro Kudo;Yasuo Hamamoto;Ken Kato;Takashi Ura

  • TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

    Takayuki Yoshino;Nobuyuki Mizunuma;Kentaro Yamazaki;Tomohiro Nishina

  • Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

    Ranee Mehra;Ranee Mehra;Tanguy Y. Seiwert;Shilpa Gupta;Shilpa Gupta;Jared Weiss

Frequent Co-Authors

Kohei Shitara
Kohei Shitara Yahoo (United Kingdom)
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Atsushi Ohtsu
Atsushi Ohtsu Juntendo University
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Toshihiko Doi
Toshihiko Doi Okayama University
Hyun Cheol Chung
Hyun Cheol Chung Yonsei University
Yasushi Yatabe
Yasushi Yatabe Nagoya University
Hideo Baba
Hideo Baba Kumamoto University
Keitaro Matsuo
Keitaro Matsuo Nagoya University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean becoming a physician. There are many alternative online pathways that offer flexible entry points into the healthcare field. For example, online bsn programs for non nurses are designed for students from non-nursing backgrounds, making it easier to transition into nursing with an undergraduate degree in another field.

If you're interested in the administrative side of healthcare, you can consider enrolling in a health administration degree program online. These accelerated degrees can prepare you for management roles in hospitals, clinics, and other health organizations.

For those looking for a career that requires less clinical interaction, many choose to pursue roles through medical billing and coding schools online. These programs often have flexible schedules and can qualify you for in-demand positions in medical offices or insurance companies.

Additionally, if standardized admissions tests are a barrier, look for nursing schools that don't require teas test. This can make the application process quicker and more accessible for many aspiring nurses.

Best Scientists Citing Kei Muro

Trending Scientists

Recently Published Articles